Kornimate/medical-research-clean huggingface dataset:
effect of yoga on life quality and immunity in breast cancer patients after operation and or chemotherapy

Conditions: Female Breast Carcinoma

Summary: the purpose of study is to investigate if yoga exercise improve life quality and immune status in breast cancer patients after complete treatment (including surgery and / or radiotherapy and / or chemotherapy)

it is well-known that exercise promote immune regulation for better life quality. however, the mechanism for better immunity and life quality is not clear. we postulate that ayurveda yoga might benefit breast cancer women with completion of operation and/or chemotherapy and radiotherapy. the benefits could be due to immune modulation, and improve health perception and life quality, and even potential decrease of cancer relapse. the study patients will do yoga twice a week for 12 weeks. the study primary endpoints are 1) to improve personal health perception, 2) to improve life quality and 3) to enhance human immunity. the study secondary endpoint will follow up the immunity changes 3 months after the intervention. we anticipate to reach the primary endpoints and to publish the primary results in one year, the secondary endpoint will complete in the second year.

Eligibility criteria:
inclusion criteria: * able to attend yoga program weekly, and fill out inform consent. * patients with breast cancer after complete treatment for at least 3 months (including surgery and / or radiotherapy and/or chemotherapy). exclusion criteria: * male * overweight * unable to do yoga exercise.
non-steroidal anti-inflammatory in cardiac surgery

Conditions: Acute Postoperative Pain; Non-steroidal Anti-inflammatory Drugs; Cardiac Surgery; Pain Intensity; Multimodal Pain Management

Summary: non-steroidal anti-inflammatory drugs (nsaid) are part the multimodal strategy in pain management after surgery. however, major concerns are raised in cardiac surgery given the potential side effects of nsaid with more bleeding and acute kidney injury. the investigators hypothesized that nsaid are safe in the early postoperative course after cardiac surgery with respect to contraindication.


Eligibility criteria:
inclusion criteria: * scheduled for cardiac surgery (aortic valve replacement, coronary artery bypass graft, mitral valve repair or replacement, intracardiac tumor, aortic root repair) * under cardiopulmonary bypass * affiliation to the french national healthcare system * written consent obtained exclusion criteria: * age\<18 * weight\<50 kg * chronic use of nsaid * mini-invasive surgery * nsaid contraindication * nsaid allergy * nefopam contraindication * paracetamol contraindication * tramadol contraindication * urgent surgery * endocarditis * immunosuppressive drug * hiv infection with cd4\<200 mm3 * organ transplantation * stage 4 or 5 chronic kidney disease * gastro duodenal ulcer * pregnancy * depression * auto immune disease

Keywords: acute postoperative pain non-steroidal anti-inflammatory drugs cardiac surgery pain intensity multimodal pain management
effectiveness of alveolar bone preservation in alveoli with infectious process

Conditions: Alveolar Bone Loss

Summary: alveolar ridge preservation (arp) is a surgical technique that aims to minimize the degree of dimensional changes following extraction. in the healing period after extraction, the alveolar bone (ab) undergoes morphological changes during the remodeling process. the changes become evident immediately after tooth extraction, with greater resorption changes observed during the first two months, and these dimensional changes can be observed 1 year after surgery.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients with indicated tooth extractions * patients who have accepted the conditions of the study exclusion criteria: * pregnant patients, breastfeeding or using oral contraceptives * smoking patients * patients with uncontrolled systemic diseases * history of autoimmune disease * previous traumatic extraction * patients taking bisphosphonates or anticoagulants * patients who are or have undergone chemotherapy and radiotherapy

Keywords: alveolar resorption alveolar process bone substitutes alveolar bone grafting
validation of a remote wireless sensor network (wsn) approach to the individualized detection of cocaine use in humans

Conditions: Cocaine Dependence

Summary: this study looks to explore the feasibility, sensitivity, validity, and specificity of a remote wireless sensor network (rwsn) approach to the detection of cocaine use/intoxication in the inpatient human laboratory, as well as in the outpatient setting ("real world"). lastly, we look to design an algorithm for reliably detecting cocaine use in real-world settings and inference techniques for understanding the relationship between cocaine use and user contexts.


Eligibility criteria:
inclusion criteria: 1. age 18 - 50 years, 2. voluntary, written, informed consent, 3. physically healthy by medical history, physical, neurological, ecg, and laboratory examinations, 4. dsm-iv criteria for cocaine abuse (305.60) or cocaine dependence (304.20) 5. recent street cocaine use in excess of amounts to be administered in the current study, 6. intravenous and/or smoked (crack/ freebase) use, 7. positive urine toxicology screen for cocaine, 8. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (β-hcg) test. exclusion criteria: 1. other drug dependence (except nicotine) as determined by urine toxicology or interview 2. \< 1 year of cocaine dependence, 3. a primary major dsm-iv psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine, 4. a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiov ascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures parameters re: elevations in vital signs are now explicitly specified under "safety features built into our one-day self-administration paradigm). 5. current use of psychotropic and/or potentially psychoactive prescription medication, 6. seeking treatment for drug abuse/dependence (for experimental cocaine component), 7. physical or laboratory (β-hcg) evidence of pregnancy. 8. current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians.
neostigmine for snoring during dise

Conditions: Snoring

Summary: the study team is seeking a novel treatment for snoring involving local application of a nerve stimulant medication, neostigmine. in this study, neostigmine will be injected into 5 sites of the soft palate during a standard procedure, drug-induced sleep endoscopy, to evaluate the effect on snoring.

snoring is a major problem, affecting 40 million americans. the disease affects patient and partner sleep quality as well as daytime function. snoring treatment is limited by device compliance (mouth appliance, positive airway pressure) and insurance does not regularly pay for these devices. surgical treatment for snoring has mixed results. as a result, there is an important need to develop new treatments for snoring. the study team is seeking a novel treatment for snoring involving local application of a nerve stimulant medication, neostigmine. in this study, neostigmine will be injected into 5 sites of the soft palate during a standard procedure, drug-induced sleep endoscopy, to evaluate the effect on snoring. if successful, development of a topical (non-injectable) version of this drug will be considered, so that the patient can apply him/herself before bedtime.

Eligibility criteria:
inclusion criteria: * snoring or mild obstructive sleep apnea * english-speaking * greater than 18 years old * able to give informed consent exclusion criteria: * on active anti-coagulation medication * pregnant women * hypersensitivity to neostigmine * peritonitis or mechanical obstruction of the intestinal or urinary tract * coronary artery disease * cardiac arrhythmia * recent acute coronary syndrome * myasthenia gravis

Keywords: neostigmine nerve stimulant medication treatments for snoring
multicentre randomised clinical trial comparing fixed vs pro re nata (prn) dosing of 700 μg dexamethasone

Conditions: Diabetic Macular Edema

Summary: multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg dexamethasone posterior segment drug delivery system (ozurdex) is as efficacious as optical coherence tomography (oct)-guided prn dosing in patients with refractory diabetic macular edema.


Eligibility criteria:
inclusion criteria: 1. subjects of either sex aged 18 years or over 2. diagnosis of diabetes mellitus (type 1 or type 2). 3. best corrected visual acuity in the study eye between ≥34 and ≤73 etdrs letters at 1m at baseline attributable to diabetic macular edema (dme) 4. on clinical exam at baseline in the study eye, retinal thickening due to diabetic macular oedema involving the centre of the macula and oct central subfield \> 300 microns despite previous therapy. 5. media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs. 6. ability to return for study visits 7. visual acuity in fellow eye ≥ 2/60 8. ability to give informed consent throughout the duration of the study main exclusion criteria: 1. macular ischaemia 2. macular oedema is considered to be due to a cause other than diabetic macular oedema. 3. co-existent ocular disease 4. an ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular oedema or alter visual acuity during the course of the study. 5. a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more.

Keywords: diabetic macular edema, ozurdex
effect of participation in virtual exercise sessions in persons with aphasia

Conditions: Aphasia, Acquired

Summary: the purpose of this study is to test the feasibility and acceptability of an online exercise program for community-dwelling individuals with aphasia, a language disorder resulting from brain damage. physical activity, language, cognitive, and quality of life outcomes will be collected to assess potential effectiveness.

approximately one-third of stroke survivors have aphasia, acquired language difficulty that affects the ability speak and understand others. however, despite documented benefits of interventions to promote physical activity (pa) after stroke, including improved health-related quality of life (qol), social and emotional benefits, and improved cognition, individuals with aphasia are often excluded from this research due to their communication difficulties. this is particularly concerning, given that individuals with aphasia are at greater risk of social isolation and depression compared to stroke survivors without aphasia. presently, limited research has been conducted that examines the effect of pa interventions in individuals with aphasia although preliminary findings suggest that benefits may exist across domains (health and disability). this study aims to better understand how pa affects the lives of individuals with aphasia. given weekly tele-instruction in pa over 10 weeks, participants' levels of pa will be monitored for the duration of the study. pre- and post-treatment measures of cognitive ability, qol, and aphasia severity will be collected and analyzed to characterize intervention effects. the results of this study will provide insight into whether pa may be an important component of future aphasia treatment.

Eligibility criteria:
inclusion criteria: * presence of aphasia * able to join exercise classes over zoom exclusion criteria: * none
lramps versus ldp in selected early-stage left-sided pancreatic cancer

Conditions: Left-sided Pancreatic Cancer

Summary: this multicenter randomized controlled clinical trial proposed the criteria for selecting patients with early-stage left-sided pancreatic cancer and aimed to compare the perioperative and oncological outcomes of patients within the criteria who underwent laparoscopic radical antegrade modular pancreatosplenectomy versus laparoscopic distal pancreatosplenectomy.

although prospective comparative studies are lacking, laparoscopic distal pancreatosplenectomy (ldp) was considered to be feasible, safe, and oncologically equivalent for treating pancreatic ductal adenocarcinoma (pdac). however, the extent of posterior resection and the oncological safety of achieving complete n1 lymph node resection in ldp remain uncertain. strasberg proposed radical antegrade modular pancreatosplenectomy (ramps) for the treatment of resectable left-sided pdac and confirmed that this technique can achieve negative margins and satisfactory survival. given the oncological equivalence of laparoscopic radical antegrade modular pancreatosplenectomy (lramps) and its advantages in short-term outcomes, several studies have assessed the feasibility of lramps as the standard treatment for resectable left-sided pdac. however, previous studies on lramps have mostly included tumors staged t2 and above, and there is currently no research on the routine use of lramps for early-stage tumors. we proposed the criteria for selecting patients with early-stage left-sided pdac: (1) diameter ≤ 4 cm; (2) located ≥ 1 cm from the celiac trunk; (3) didn't invade the fascial layer behind the pancreas. this multicenter open-label randomized controlled clinical trial aims to compare the perioperative and oncological outcomes of patients within the criteria who underwent lramps versus ldp.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as resectable left-sided pancreatic cancer before surgery. * imaging tumor diameter ≤ 4 cm. * located ≥ 1cm from the celiac trunk. * tumor didn't invade the fascial layer behind the pancreas. * be able to comply with research protocol. * voluntary participation and signed informed consent. exclusion criteria: * received neoadjuvant therapy. * presence of liver or other distant metastasis. * multifocal or recurrent disease. * history of other malignancies. * simultaneously participating in other clinical trials.

Keywords: left-sided pancreatic cancer early-stage tumor laparoscopic radical antegrade modular pancreatosplenectomy laparoscopic distal pancreatosplecnectomy surgical complication oncologic prognosis
a multi-center study to determine the prevalence and influence of pertussis on subacute cough in shenzhen

Conditions: Pertussis; Chronic Cough

Summary: a prospective, multi-center, observational clinical trail. aim to evaluate the real incidence of copd pertussis and the impact of pertussis on subaute cough.

1. investigate the incidence and epidemiological characteristics of pertussis infection in subaute cough population. 2. to explore the relationship between pertussis infection and subaute cough.

Eligibility criteria:
inclusion criteria: * the cough lasts 3 to 8 weeks and there is no obvious evidence of lung disease on chest x-ray. exclusion criteria: * 1. major diseases except subaute cough; 2. significant abnormality in laboratory examination; 3. clinical diagnosis of lung cancer, bronchiectasis, pneumoconiosis or other simple restrictive ventilation dysfunction; 4. patients with a history of asthma, allergic rhinitis, or a blood eosinophil count of 2600/mm3 (0.6x10\^9/l) within 4 weeks; 5. currently suffering from active tuberculosis; 6. patients with life-threatening pulmonary embolism, or al-antitrypsin deficiency, or cystic fibrosis; 7. patients who have undergone lung resection.
bendamustine and mitoxantrone in treating patients with relapsed or refractory chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: rationale: drugs used in chemotherapy, such as bendamustine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more cancer cells. purpose: this phase ii trial is studying how well giving bendamustine together with mitoxantrone works in treating patients with relapsed or refractory b-cell chronic lymphocytic leukemia.

objectives: primary * determine the response rate (remission rate) in patients with relapsed or refractory b-cell chronic lymphocytic leukemia (cll) treated with bendamustine and mitoxantrone hydrochloride. secondary * determine the progression-free survival and overall survival of patients treated with this regimen. * determine the safety and tolerability of this regimen in these patients. outline: this is a non-randomized, multicenter study. patients receive bendamustine iv over 1 hour on days1-3 and mitoxantrone hydrochloride iv over 30 minutes on day 1. treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. patients with responding disease (i.e., complete response or partial response) after 2 courses receive 2 additional courses of treatment for a total of 4 courses. after completion of study treatment, patients are followed periodically for survival. projected accrual: a total 60 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * cytologically and immunophenotypically confirmed diagnosis of b-cell chronic lymphocytic leukemia (cll) * relapsed or refractory disease patient characteristics: * no known hypersensitivity to any of the study medications * no uncontrolled infection * no impaired organ function prior concurrent therapy: * not specified

Keywords: b-cell chronic lymphocytic leukemia refractory chronic lymphocytic leukemia
clinical trial of iv okn-007 in a pilot cohort of human recurrent malignant glioma patients

Conditions: Recurrent Malignant Glioma

Summary: this is an open label phase 1b clinical trial of iv administration of okn-007 in a pilot cohort of human recurrent malignant glioma patients. all patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (avastin). patients with unequivocal recurrence (first or greater) established by mri with and without contrast (e.g., gd-dtpa (gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for okn-007 treatment on this protocol.


Eligibility criteria:
inclusion criteria: 1. confirmed histopathology of who grade iii glioma or who grade iv gbm at primary diagnosis 2. unequivocal radiographic evidence of tumor progression by mri within 14 days prior to registration 3. prior radiotherapy 4. prior temozolomide treatment 5. last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered) 6. karnofsky performance status greater than or equal to 60% 7. full recovery (\< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent 8. adequate renal, liver and bone marrow function: * leukocytes \>3,000/mcl * absolute neutrophil count \>1,500/mcl * platelets \>100,000/mcl * total bilirubin within normal limits * ast / alt (sgpt) \<2.5 x uln * creatinine within normal limits 9. patients must be \>_18 years of age exclusion criteria: 1. second primary malignancy (except adequately treated basal cell carcinoma of the skin). patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible 2. have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry 3. serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ecg) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study 4. patients with moderate or severe renal impairment (calculated creatinine clearance of \< 60 ml/min) 5. patients with sodium, potassium, or creatinine serum electrolytes \> grade 2. 6. patients with pt/ptt above the upper limit of normal 7. screening ecg abnormality documented by the investigator as medically significant
the effectiveness of lifestyle redesign training in elderly with cognitive decline

Conditions: Aging

Summary: taiwan is already an aging society due to the rapid increase of the aging population. to cope with this situation, it is necessary to make preparations for the care of the elderly. world health organization (who) proposed aging health strategy in recent years, and the community participation is the most important for the elderly. the courses provided by the community empowering are important to promote the healthy life of the elderly. however, at this stage, there are relatively few courses related to cognitive functions, life-style activities and aging education. it is needed to add more courses related to multi-domain.

taiwan is already an aging society due to the rapid increase of the aging population. to cope with this situation, it is necessary to make preparations for the care of the elderly. world health organization (who) proposed aging health strategy in recent years, and the community participation is the most important for the elderly. the courses provided by the community empowering are important to promote the healthy life of the elderly. however, at this stage, there are relatively few courses related to cognitive functions, life-style activities and aging education. it is needed to add more courses related to multi-domain. investigators anticipate recruiting a total of 50 participants with cognitive decline. the participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training. the programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. investigators plan to assess the participants before and after the intervention programs. investigators expect that elders receiving training will improve on outcome measures. the results of the study will provide evidence of interventions for elderly with cognitive decline.

Eligibility criteria:
inclusion criteria: * able to follow instruction (mmse\>= 20) * self- or informant-reported memory or cognitive complaint. exclusion criteria: * recent myocardial infarction,heart failure,recent heart surgery, * severe asthma, concomitant with other neurological disorders, or joint deformity that might prevents them performing exercise or cognitive training.

Keywords: life-style activities cognitive functions